M Bogorodskaya1,2, A Lyass3, T F Mahoney4, L H Borowsky5, P Sen6, F K Swirski7, S Srinivasa8, C T Longenecker2, J M Massaro4, R B D'Agostino3, V A Triant5,6,9. 1. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2. Case Western Reserve University School of Medicine, Cleveland, OH, USA. 3. Department of Mathematics and Statistics, Boston University, Boston, MA, USA. 4. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 5. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 6. Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 7. Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. 8. Program in Nutritional Metabolism, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 9. Mongan Institute, Massachusetts General Hospital, Boston, MA, USA.
Abstract
OBJECTIVES: Cardiovascular risk is increased in people living with HIV (PLWH). In HIV-uninfected populations, total absolute monocyte count (AMC) has been shown to be predictive of future cardiovascular events (CVEs). We sought to determine whether AMC predicts CVEs in PLWH independent of established and HIV-related cardiovascular risk factors. METHODS: We identified all PLWH within the Partners HIV Cohort without factors that could confound the monocyte count. CVE was defined as fatal or non-fatal acute myocardial infarction or ischaemic stroke. Baseline-measured AMC was defined as the average of all outpatient AMC counts a year before and after the baseline date. Multivariable Cox proportional hazards models were used to assess the association of baseline AMC with CVEs. RESULTS: Our cohort consisted of 1980 patients, with median follow-up of 10.9 years and 182 CVEs. Mean (± SD) age was 41.9 ± 9.3 years; 73.0% were male. Mean CD4 count was 506.3 ± 307.1 cells/µL, 48% had HIV viral load (VL) < 400 copies/mL, and 87% were on antiretroviral therapy. Mean AMC was 0.38 × 103 ± 0.13 cells/µL. In multivariable modelling adjusted for traditional CV risk factors, CD4 cell count, and HIV VL, AMC quartile 2 (Q2) (HR = 1.01, P = 0.98), Q3 (HR = 1.07, P = 0.76), and Q4 (HR = 0.97, P = 0.89) were not significantly predictive of CVE compared with Q1. DISCUSSION: Baseline AMC was not associated with long-term CVEs in PLWH. AMC obtained in routine clinical encounters does not appear to enhance CV risk stratification in PLWH.
OBJECTIVES: Cardiovascular risk is increased in people living with HIV (PLWH). In HIV-uninfected populations, total absolute monocyte count (AMC) has been shown to be predictive of future cardiovascular events (CVEs). We sought to determine whether AMC predicts CVEs in PLWH independent of established and HIV-related cardiovascular risk factors. METHODS: We identified all PLWH within the Partners HIV Cohort without factors that could confound the monocyte count. CVE was defined as fatal or non-fatal acute myocardial infarction or ischaemic stroke. Baseline-measured AMC was defined as the average of all outpatient AMC counts a year before and after the baseline date. Multivariable Cox proportional hazards models were used to assess the association of baseline AMC with CVEs. RESULTS: Our cohort consisted of 1980 patients, with median follow-up of 10.9 years and 182 CVEs. Mean (± SD) age was 41.9 ± 9.3 years; 73.0% were male. Mean CD4 count was 506.3 ± 307.1 cells/µL, 48% had HIV viral load (VL) < 400 copies/mL, and 87% were on antiretroviral therapy. Mean AMC was 0.38 × 103 ± 0.13 cells/µL. In multivariable modelling adjusted for traditional CV risk factors, CD4 cell count, and HIV VL, AMC quartile 2 (Q2) (HR = 1.01, P = 0.98), Q3 (HR = 1.07, P = 0.76), and Q4 (HR = 0.97, P = 0.89) were not significantly predictive of CVE compared with Q1. DISCUSSION: Baseline AMC was not associated with long-term CVEs in PLWH. AMC obtained in routine clinical encounters does not appear to enhance CV risk stratification in PLWH.
Authors: Kyrill S Rogacev; Bodo Cremers; Adam M Zawada; Sarah Seiler; Nadine Binder; Philipp Ege; Gunnar Große-Dunker; Isabel Heisel; Florian Hornof; Jana Jeken; Niko M Rebling; Christof Ulrich; Bruno Scheller; Michael Böhm; Danilo Fliser; Gunnar H Heine Journal: J Am Coll Cardiol Date: 2012-09-19 Impact factor: 24.094
Authors: Virginia A Triant; Susan Regan; Hang Lee; Paul E Sax; James B Meigs; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Matthew J Feinstein; Ehete Bahiru; Chad Achenbach; Christopher T Longenecker; Priscilla Hsue; Kaku So-Armah; Matthew S Freiberg; Donald M Lloyd-Jones Journal: Am J Cardiol Date: 2015-11-06 Impact factor: 2.778
Authors: J S Rana; S M Boekholdt; P M Ridker; J W Jukema; R Luben; S A Bingham; N E Day; N J Wareham; J J P Kastelein; K-T Khaw Journal: J Intern Med Date: 2007-10-01 Impact factor: 8.989
Authors: Joshua J Anzinger; Tiffany R Butterfield; Thomas A Angelovich; Suzanne M Crowe; Clovis S Palmer Journal: J Immunol Res Date: 2014-06-12 Impact factor: 4.818
Authors: Nath Zungsontiporn; Raquel R Tello; Guangxiang Zhang; Brooks I Mitchell; Matthew Budoff; Kalpana J Kallianpur; Beau K Nakamoto; Sheila M Keating; Philip J Norris; Lishomwa C Ndhlovu; Scott A Souza; Cecilia M Shikuma; Dominic C Chow Journal: PLoS One Date: 2016-02-11 Impact factor: 3.240
Authors: Clay Bavinger; Eran Bendavid; Katherine Niehaus; Richard A Olshen; Ingram Olkin; Vandana Sundaram; Nicole Wein; Mark Holodniy; Nanjiang Hou; Douglas K Owens; Manisha Desai Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069